📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. (2019)

First Author: CRASH-3 Trial Collaborators

Attributed to: The CRASH-3 Trial: Tranexamic acid for the treatment of significant traumatic brain injury. funded by GCRF

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(19)32233-0

PubMed Identifier: 31623894

Publication URI: http://europepmc.org/abstract/MED/31623894

Type: Journal Article/Review

Volume: 394

Parent Publication: Lancet (London, England)

Issue: 10210

ISSN: 0140-6736